Home > Cardiology > Reduced doses rivaroxaban and apixaban may be beneficial to reduce renal impairment

Reduced doses rivaroxaban and apixaban may be beneficial to reduce renal impairment

Conference
ESC 2019
Trial
RELOADED
Results from the first observational study using retrospective anonymised data from a German claims database showed that reduced doses of rivaroxaban and apixaban may have a beneficial effect in comparison with phenprocoumon in the outcome of renal function worsening over time. This effect was more pronounced for the risk reduction associated with rivaroxaban in end-stage renal disease (ESRD)/dialysis and specifically also related to a significant risk reduction for acute kidney injury (AKI). Data on the effectiveness and safety of non-vitamin K oral anticoagulants (NOACs) in patients with non-valvular atrial fibrillation (NVAF) and renal disease is scarce. Bonnemeier and colleagues aimed to investigate the risk of renal function worsening in new users of NOACs vs phenprocoumon. The investicators conducted a new-user cohort study (one year washout period) in patients with NVAF and renal disease, which was defined by either an extended list of ICD10 codes (...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on